Weiss Ratings Reiterates Sell (D-) Rating for Alpha Tau Medical (NASDAQ:DRTS)

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for Alpha Tau Medical (NASDAQ:DRTS), indicating a negative outlook for the stock.
• In contrast, HC Wainwright maintained a "buy" rating with a target price of $9.00, suggesting a more favorable perspective from some analysts.
• Alpha Tau Medical's recent earnings report showed a loss of $0.13 per share, missing analysts' expectations, and the company has a market capitalization of approximately $356.67 million.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report)'s stock had its "sell (d-)" rating reiterated by analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

Separately, HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Alpha Tau Medical in a research report on Wednesday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $9.00.

Alpha Tau Medical Stock Performance

DRTS stock traded down $0.01 during midday trading on Friday, reaching $4.21. 26,255 shares of the company's stock traded hands, compared to its average volume of 63,160. The firm has a market capitalization of $356.67 million, a PE ratio of -8.76 and a beta of 1.07. The company has a 50-day moving average price of $3.80 and a two-hundred day moving average price of $3.24. Alpha Tau Medical has a 52 week low of $2.14 and a 52 week high of $4.69. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.81 and a current ratio of 10.52.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities analysts anticipate that Alpha Tau Medical will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alpha Tau Medical stock. Kovitz Investment Group Partners LLC lifted its position in Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) by 601.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 226,320 shares of the company's stock after purchasing an additional 194,055 shares during the quarter. Kovitz Investment Group Partners LLC owned about 0.32% of Alpha Tau Medical worth $568,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.65% of the company's stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.